Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says

 
• By Anju Ghangurde

Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.

FORMER FDA COMMISSIONER SCOTT GOTTLIEB SAYS CLINICAL TRIALS DURING A PANDEMIC MAY NEED MORE DIRECTED FLIGHT PATHS. • Source: Shutterstock

More from Clinical Trials

More from R&D